174 related articles for article (PubMed ID: 18021605)
1. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
2. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
3. Rosaceiform eruption induced by erlotinib.
Patrizi A; Bianchi F; Neri I
Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib-induced pustular eruption.
Cusano F; Ferrara G; Barletta E; Ingordo V
G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
[TBL] [Abstract][Full Text] [Related]
8. A case of bullous dermatitis induced by erlotinib.
Oteri A; Cattaneo MT; Filipazzi V; Ferrario S; Gambaro A; Isabella L; Tosca N; Clementi E; Radice S; Piazza E
Oncologist; 2009 Dec; 14(12):1201-4. PubMed ID: 19965913
[TBL] [Abstract][Full Text] [Related]
9. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor inhibitor-related folliculitis.
Tangri N; Al Hammadi A; Gerstein W
Dermatitis; 2007 Sep; 18(3):178-9. PubMed ID: 17725926
[No Abstract] [Full Text] [Related]
11. Erlotinib-induced rash spares previously irradiated skin.
Lips IM; Koster ME; Houwing RH; Vonk EJ
Strahlenther Onkol; 2011 Aug; 187(8):499-501. PubMed ID: 21789741
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
14. [Acneiforme rash in woman with pulmonary adenocarcinoma].
Navarro Martín M; Rodríguez Sánchez C; Delgado Fernández C; Mezquita Pérez L; Cruz Hernández JJ
Rev Clin Esp; 2008 May; 208(5):251-2. PubMed ID: 18457638
[No Abstract] [Full Text] [Related]
15. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
16. Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Shrimali RK; Correa PD; Rizwanullah M
BMJ Case Rep; 2008; 2008():bcr0620080075. PubMed ID: 21716815
[No Abstract] [Full Text] [Related]
17. Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Chen KL; Lin CC; Cho YT; Yang CW; Sheen YS; Tsai HE; Chu CY
JAMA Dermatol; 2016 Mar; 152(3):340-2. PubMed ID: 26649681
[No Abstract] [Full Text] [Related]
18. Rhabdomyolysis from erlotinib: a case report.
Moscetti L; Nelli F; Ruggeri EM
Tumori; 2011; 97(3):415-6. PubMed ID: 21789026
[No Abstract] [Full Text] [Related]
19. Erlotinib-Induced Transverse Fissure-Like Skin Lesions of Fingers.
Sadeghi M; Loftus R; Dasanu CA
Conn Med; 2016 Sep; 80(7):405-407. PubMed ID: 29782127
[TBL] [Abstract][Full Text] [Related]
20. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]